Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status approved
ATC Code L02BX03
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165
UNII G819A456D0
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lumbar spinal stenosis15.10.04.008; 17.10.03.0040.000334%-
Metastases to bone15.09.03.006; 16.22.02.0050.006440%-
Metastases to lymph nodes01.09.01.015; 16.22.02.0060.001001%-
Penile size reduced21.12.01.0180.001135%-
Pernicious anaemia01.03.01.003; 07.17.01.004; 10.04.01.0070.000334%-
Prostate cancer recurrent16.25.01.005; 21.04.02.0080.000501%-
Prostate cancer stage IV16.25.01.007; 21.04.02.0100.000734%-
Small cell carcinoma16.16.01.0170.000501%-
Urinary bladder haemorrhage20.03.01.023; 24.07.01.0860.001635%-
Metastases to bone marrow01.05.01.022; 16.22.02.0130.000667%-
Metastases to meninges16.22.02.003; 17.02.10.0120.000334%-
Neuroendocrine tumour05.08.01.013; 16.24.01.0090.000901%-
Meningorrhagia12.01.10.016; 17.08.01.056; 24.07.04.0300.000501%-
Lymphangiosis carcinomatosa01.09.01.027; 16.22.02.009; 24.09.02.0070.000501%-
Neuroendocrine carcinoma05.08.01.011; 16.24.01.0070.000334%-
Pancreatic carcinoma stage IV07.21.09.008; 16.13.10.0050.000334%-
Hormone-refractory prostate cancer16.25.01.004; 21.04.02.007---
Sarcopenia15.05.06.0040.000334%-
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.0200.001235%-
Internal haemorrhage24.07.01.0720.001502%-
Acquired apparent mineralocorticoid excess05.01.01.008; 14.05.01.012; 24.08.04.0080.000501%-
Biliary obstruction09.02.02.0050.000334%-
Dilated cardiomyopathy02.04.01.0170.000501%-
Disease complication08.01.03.0870.000667%-
Gait inability08.01.02.011; 17.02.05.0690.003036%-
Hepatic cytolysis09.01.07.0360.000501%-
Hyperglycaemic hyperosmolar nonketotic syndrome05.07.04.009; 14.07.04.009; 17.02.04.0220.000501%-
Immobilisation syndrome08.01.03.092; 15.03.05.0170.000501%-
Neuroendocrine cancer of the prostate metastatic05.08.01.019; 16.25.01.008; 21.04.02.0120.000334%-
Physical deconditioning08.01.03.0960.000734%-
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages